What's in Biofrontera Bioscience GmbH's pipeline?

Biofrontera Bioscience GmbH has 4 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with Biofrontera Bioscience GmbH's portfolio?

Top competitors by shared drug class: DUSA Pharmaceuticals, Inc., Galderma R&D, Joint Authority for Päijät-Häme Social and Health Care, National Cancer Center, Korea, Photocure.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/biofrontera-bioscience-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Biofrontera Bioscience GmbH — Portfolio Competitive Intelligence Brief

Biofrontera Bioscience GmbH pipeline: 0 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Placebo to BF-200 ALA gel	Placebo to BF-200 ALA gel	phase 3	Photodynamic therapy agent	Protoporphyrin IX (via aminolevulinic acid metabolism)	Dermatology/Oncology

Therapeutic area mix

Dermatology · 2
Dermatology/Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

DUSA Pharmaceuticals, Inc. · 1 shared drug class
Galderma R&D · 1 shared drug class
Joint Authority for Päijät-Häme Social and Health Care · 1 shared drug class
National Cancer Center, Korea · 1 shared drug class
Photocure · 1 shared drug class
Psoriasis Treatment Center of Central New Jersey · 1 shared drug class
Steba Biotech S.A. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Biofrontera Bioscience GmbH:

Cite this brief

Drug Landscape (2026). Biofrontera Bioscience GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biofrontera-bioscience-gmbh. Accessed 2026-05-15.